The point of no return for Merrimack? Cancer drug developer axes yet another drug and more staff
Merrimack just can’t catch a break.
On Thursday, the company said it was abandoning its experimental drug, MM-310, after an early-stage study involving patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
